Integra LifeSciences Holdings (IART) 2002年年度报告「NASDAQ」.pdf

1、OUR MISSIONIntegra LifeSciences Holdings Corporation,through internal product development,acquisitions andstrategic partnerships seeks to be a world leader in providing customers with clinically relevant,inno-vative and cost-effective products that improve the quality of life.Presidents MessageTo Ou

2、r Stockholders:In 2002 we achieved record revenues,operating cash flow and net income while continuing to develop ourextensive product offerings and global infrastructure.We grew total revenues to$117.8 million in 2002,a 26%increaseover 2001,and reported our second full year of profitability.Net inc

3、ome totaled$35.3 million in 2002 as compared tonet income of$26.2 million in 2001,while cash flows generated from operations in 2002 totaled$32.0 millionbyfar our best performance ever.We have continued to expand our sales and distribution channels.We market most of our products directly throughthre

4、e separate sales forces:Integra NeuroSciences(calling on neurosurgery and neurotrauma),Integra Padgett(callingon burn,plastic and reconstructive surgery)and JARITSurgical Instruments(calling on traditional and minimally invasivesurgery).Our global selling organization now has over 150 sales,marketin

5、g,and clinical people providing unparalleledproduct support,customer service and clinical education.We also manufacture medical devices and biomaterials for sale to other companies on a private label basis or throughstrategic alliances.In 2002,Medtronic Sofamor Danek launched its bone regeneration g

6、raft for use in spinal fusionprocedures.This product includes the Absorbable Collagen Sponge that we developed and manufacture.Additionally,we expanded the indications for our INTEGRADermal Regeneration Template to include reconstructive surgery.Acquisitions also contributed to our growth last year.